IR News

Sep. 23, 2020Print(PDF/98KB)Corporate

Sumitomo Dainippon Pharma Establishes a Subsidiary in Taiwan

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that on September 15, 2020 it established Sumitomo Pharmaceuticals Taiwan Co., Ltd. (hereinafter, "SPTW") as a wholly owned subsidiary of Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. (hereinafter, "SPAP"), a wholly owned subsidiary of Sumitomo Dainippon Pharma.

In the future, SPTW will start selling our pharmaceutical products in Taiwan. From its subsidiaries in China, Singapore, and Thailand, Sumitomo Dainippon Pharma is dedicating its focus to the fast-growing Asian market. Now that we have a base for autonomous operations in Taiwan, we intend to further expand our business in the Asian market.

<Reference: About Sumitomo Pharmaceuticals Taiwan Co., Ltd.>

Company Name Sumitomo Pharmaceuticals Taiwan Co., Ltd.
Establishment September 15, 2020
Representative Toyohiro Yoneda
Share capital 35.0 million New Taiwan dollar (approx. 123.0 million yen*)
Number of employees 16
Functions Sale of ethical drugs and provision and collection of information on products to/from medical professionals in Taiwan
Ownership SPAP
Location Taipei

* 1 New Taiwan dollar = 3.5 yen